CETUS  CTUS CANCER DRUG TO GET EUROPE PATENT EMERYVILLE CALIF MARCH 16 CETUS CORP SAID THE EUROPEAN PATENT OFFICE ALLOWED AND INTENDS TO GRANT THE COMPANY A PATENT FOR PHARMACEUTICAL AND VETERINARY PREPARATIONS OF GENETICALLY ENGINEERED INTERLEUKIN 2 ANALOG INTERLEUKEN 2 IS AN IMMUNE MODULATING PROTEIN CURRENTLY UNDERGOING CLINICAL TRIALS IN THE UNITED STATES AND EUROPE FOR POTENTIAL USE IN THE TREATMENT OF VARIOUS FORMS OF CANCER CETUS SAID IT SAID THE ALLOWANCE IS THE FIRST STEP IN THE PATENT PROCESS FOLLOWING ALLOWANCE THE PATENT IS PUBLISHED FOR OPPOSITION AND A NINE MONTH PERIOD BEGINS DURING WHICH INTERESTED PARTIES HAVE AN OPPORTUNITY TO VOICE ANY OBJECTIONS TO THE PATENT CETUS SAID   